Eden Research plc Board Changes (1711S)
29 September 2017 - 4:03PM
UK Regulatory
TIDMEDEN
RNS Number : 1711S
Eden Research plc
29 September 2017
29 September 2017
Eden Research plc
("Eden" or "Company")
Board Changes
Eden Research plc (AIM: EDEN), the AIM listed company that
provides breakthrough natural microencapsulation technologies to
the global agrochemicals, animal health and consumer products
industries, announces that it has appointed Lykele van der Broek as
Non-Executive Director and Chairman-designate with effect from the
1 October 2017.
Eden's current Chairman, Tom Lupton, is to retire from his role
as Non-Executive Director and Chairman on the 31 December 2017. Tom
has been Chairman of the Company since 2014. Lykele will succeed
Tom as Chairman from the 1 January 2018.
Lykele has over 30 years of experience in the agriculture
sector. He was previously Chief Operating Officer and a member of
the Board of Management at Bayer Crop Science, Head of Bayer Animal
Health, and is currently a Non-Executive Director for FTSE 250
constituent, Genus plc.
Tom Lupton, Chairman, commented: "I have greatly enjoyed my time
with Eden Research. The Company is now in a much stronger position,
as is evident in the recent Interim results announcement, and
Eden's commercial progress continues to build. I am delighted
Lykele van der Broek has agreed to join the Board. He has deep
experience of our sector, and I look forward to watching Eden
Research grow under his Chairmanship. I wish Sean Smith and the
management team every success for the future."
Sean Smith, Chief Executive Officer, said: "I would like to
thank Tom for his significant contribution to Eden Research over
the last five years and specifically as our Chairman over the last
three and a half years. Tom has overseen significant regulatory and
commercial progress at Eden during his time at the Company and we
wish him the very best for the future.
I am pleased to welcome Lykele to the Board as Non-Executive
Director and Chairman-designate. Lykele has a wealth of experience
in the agriculture and animal health sectors and will be an asset
to the Board and the Company. We look forward to working with him
over the coming years."
Lykele van der Broek, Chairman designate, commented: "I have
watched the commercial progress that Eden has made in recent years
and am delighted to be joining the Company and to taking over from
Tom in 2018. This is a very exciting period for Eden and I look
forward to helping develop the business further."
Save as set out in the additional information section below
there are no further disclosures required to be made in respect of
the appointments under Schedule 2(g) of the AIM Rules for
Companies.
For further information contact:
Eden Research plc www.edenresearch.com
Sean Smith
Alex Abrey 01285 359 555
Shore Capital (Nomad) 020 7408 4090
Stephane Auton / Patrick
Castle
Powerscourt 020 7250 1446
Samantha Trillwood
Additional information
Full name Lykele Jurrit van der Broek
----------------------------------- ----------------------------
Age: 63 years old
----------------------------------- ----------------------------
Current directorships: Genus plc
Peertje voor de Dorst B.V.
----------------------------------- ----------------------------
Directorships held in last 5 years Bayer CropScience AG
----------------------------------- ----------------------------
Notes:
Eden Research is a technology development and commercialisation
company with intellectual property and expertise in encapsulation,
terpenes and environmentally friendly technologies to provide
naturally occurring solutions for the global agrochemicals, animal
health, and consumer product industries.
Eden's encapsulation technology harnesses the biocidal efficacy
of naturally occurring chemicals produced by plants (terpenes) and
can also be used with both natural and synthetic compounds to
enhance their performance and ease-of-use. The technology uses
yeast cells that are a by-product of numerous commercial production
processes to deliver a slow release of natural compounds for
agricultural and non-agricultural uses. Terpenes are already widely
used in the food flavouring, cosmetics and pharmaceutical
industries.
Historically, terpenes have had limited commercial use in the
agrochemical sector due to their volatility, phytotoxicity and poor
solubility. Eden's platform encapsulation technology provides a
unique, environmentally friendly solution to these problems and
enables terpenes to be used as effective, low-risk
agrochemicals.
Eden is developing these technologies through innovative
research and a series of commercial production, marketing and
distribution partnerships.
The Company has a number of patents and a pipeline of products
at differing stages of development targeting specific areas of the
global agrochemicals industry. To date, the Company has invested in
the region of GBP12m in developing and protecting its intellectual
property and seeking regulatory approval for products that rely
upon the Company's technologies. Revenues earned by the Company
have been modest whilst the Company has concentrated on securing
patent protection for its intellectual property, gaining regulatory
approvals, identifying suitable industrial partners, and entering
into commercial agreements.
In May 2013, the three actives that comprise Eden's first
commercial product, 3AEY, were approved as new ingredients for use
in plant protection products. This represented a major milestone in
the commercialisation of Eden's technology and is a significant
accomplishment for any company. To illustrate this point, one
should note that in all of 2013, Eden's approvals represented 3 of
only 10 new active ingredients approved by the EC.
3AEY has been authorised for sale in Kenya, Malta, Greece,
Bulgaria, Spain, Italy, France, Cyprus, Albania and Portugal.
Eden was admitted to trading on AIM on 11 May 2012 and trades
under the symbol EDEN.
For more information about Eden, please visit:
www.edenresearch.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOALPMMTMBMTTAR
(END) Dow Jones Newswires
September 29, 2017 02:03 ET (06:03 GMT)
Eden Research (LSE:EDEN)
Historical Stock Chart
From Apr 2024 to May 2024
Eden Research (LSE:EDEN)
Historical Stock Chart
From May 2023 to May 2024